8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________

FORM 8-K

______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 25, 2014

Cytomedix, Inc.

(Exact name of registrant as specified in its charter)

______________

Delaware	01-32518	23-3011702
(State or Other Jurisdiction	(Commission	(I.R.S. Employer
of Incorporation)	File Number)	Identification No.)

209 Perry Parkway, Suite 7, Gaithersburg, MD 20877

(Address of Principal Executive Office) (Zip Code)

240-499-2680

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement

Closing of the Second Tranche of the Deerfield Financing

As previously disclosed, Cytomedix, Inc., a Delaware corporation (the “Company”), entered into a Facility Agreement dated as of March 31, 2014 (the “Facility Agreement”) with affiliates of Deerfield Management Company, L.P. (“Deerfield”), pursuant to which Deerfield agreed to loan to the Company up to $35 million, subject to the terms and conditions set forth in the Facility Agreement (the “Deerfield Financing”). The first draw in the amount of $9 million was closed on March 31, 2014 (the “First Draw”).

On June 25, 2014, following satisfaction of closing conditions, the Company completed the second draw under the Facility Agreement in the aggregate amount of $26 million (the “Second Draw”). Further, pursuant to the terms of the Facility Agreement and at the time of the Second Draw, the Company issued to Deerfield 67,500,000 warrants to purchase shares of the Company’s common stock at the exercise price of $0.52 per share (the “Deerfield Warrants”), subject to adjustments. These warrants are substantially identical to the warrants issued to Deerfield in the connection with the First Draw and contain, among other things, limitations that prevent the holder of any warrants from acquiring shares upon exercise of a warrant that would result in the number of shares beneficially owned by it and its affiliates to exceed 9.98% of the total number of shares of our common stock then issued and outstanding. The Company relied on the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”), for the issuance of the Deerfield Warrants and expects to rely on such exemption for any issuance of its shares issuable upon exercise of the Deerfield Warrants (the “Deerfield Warrant Shares”). The Deerfield Warrants and the Deerfield Warrant Shares have not been registered under the Securities Act or state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. Pursuant to the terms of the registration rights agreement dated as of the date of the Facility Agreement, as amended below, the Company agreed to file a registration statement to register, among others, the resale of the shares of its common stock issuable upon conversion of the Deerfield notes and exercise of the Deerfield Warrants issued and sold in the Second Draw, subject to limitations contained in such instruments and agreements.

In connection with the closing of the Second Draw, the Company and Deerfield entered into an amendment to the Facility Agreement, dated as of June 25, 2014 (the “Amendment”). The parties agreed to amend the payment of the Yield Enhancement Payment referenced in the Facility Agreement which represented a payment of 3% of the principal amount drawn under the Deerfield facility, originally contemplated to be payable in shares of the Company’s common stock or in cash. Under the terms of the Amendment, the Yield Enhancement Payment in connection with the Second Draw will be payable in shares of the Company’s common stock (the “Yield Enhancement Shares”), which number of shares will be equal to the Yield Enhancement Payment divided by the lesser of (x) the volume weighted average price of the Company’s common stock for the five consecutive trading days period (the “5-day VWAP”) prior to the filing date of the Company’s registration statement registering, among other things, the resale of the Deerfield note conversion shares and the Deerfield Warrant Shares of our common stock, including the Yield Enhancement Shares (the “S-1 Registration Statement”) or (y) the closing bid price for the Company’s common stock on the last trading day prior to the filing of the S-1 Registration Statement, provided that such closing bid price is no less than 93% of the last closing price for the Company’s common stock during regular trading hours on such date (the “Yield Enhancement Price”). Finally, in the event that the S-1 Registration Statement is not declared effective by the Securities and Exchange Commission within twenty trading days following the filing of the S-1 Registration Statement, the Company will make a cash payment to Deerfield in the amount equal to the product of (x) the number of the Yield Enhancement Shares and (y) the difference between (i) the Yield Enhancement Price and (ii) the price equal to the 5-day VWAP period beginning on the trading day immediately following the effectiveness of the S-1 Registration Statement.

The foregoing description of the Amendment to the Facility Agreement does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such document, which is filed as exhibit to this filing and is incorporated herein by reference. Such document contains representations and warranties by each of the parties thereto. The representations, warranties and covenants contained in such document were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and (i) should not be treated as statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii) may have been qualified in the agreement by disclosures that were made to the other party in connection with the negotiation of the agreement; (iii) may apply contract standards of “materiality” that are different from “materiality” under the applicable securities laws; and (iv) were made only as of the date of such agreement or such other date or dates as may be specified in the agreement.

In connection with the closing of the second draw on the Deerfield facility, the Company paid to BTIG, LLC, the placement agent in connection with this transaction (the “Placement Agent”), $1.71 million cash commission and a warrant to acquire 3,525,000 shares of the Company’s common stock on the terms and provisions substantially similar to the Deerfield Warrants.

Upon the closing of the second draw on the Deerfield facility and following the retirement of JP Nevada Trust debt (described below), net proceeds to the Company in the amount of approximately $22.13 million will be utilized for general corporate and working capital purposes.

Payoff and Discharge of the JP Nevada Trust Promissory Note

On June 23, 2014, the Company paid approximately $2.16 million to extinguish the secured debt (including interest accrued to date and applicable fees) evidenced by a promissory note dated April 28, 2011, held by JP Nevada Trust thereby discharging the Note and the debt thereunder. The Company has no further obligations or liability under the Notes. The financial impact of the foregoing payoff will be reflected in the Company's financial statements for the quarterly period ended June 30, 2014.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 is hereby incorporated by reference into this Item 2.03.

Item 3.02. Unregistered Sale of Equity Securities.

The information set forth in Item 1.01 is hereby incorporated by referenced into this Item 3.02.

Forward-Looking Statements

This Current Report on Form 8-K may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Please refer to the risks detailed from time to time in the Company’s SEC reports, including its Annual Report Form 10-K for the year ended December 31, 2013, filed on March 31, 2014 with the SEC, as well as other periodic filings on Form 10-Q and filings on Form 8-K, for additional factors that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

Item 8.01 Other Events

On June 26, 2014, the Company issued a press release relating to the closing of the Second Draw of the Deerfield facility. A copy of this press release is attached hereto as Exhibit 99.1.

The information in Exhibit 99.1 is not “filed” pursuant to the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any Securities Act registration statements. Additionally, the submission of this report on Form 8-K is not an admission as to the materiality of any information in this report that is required to be disclosed solely by Regulation FD.

Item 9.01 Exhibits

10.1	Amendment to the Facility Agreement dated as of June 25, 2014.
99.1	Press release dated June 26, 2014.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Cytomedix, Inc.
By:	/s/ Martin P. Rosendale
	Martin P. Rosendale Chief Executive Officer

Date: July 1, 2014

EX-10.1

FIRST AMENDMENT TO FACILITY AGREEMENT
AND REGISTRATION RIGHTS AGREEMENT

FIRST AMENDMENT TO FACILITY AGREEMENT AND REGISTRATION RIGHTS AGREEMENT (this “Amendment”), dated as of June 25, 2014, by and among CYTOMEDIX, INC., a Delaware corporation (the “Borrower”), DEERFIELD PRIVATE DESIGN FUND II, L.P. (“DPDF”), DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P. (“DFPDI”), DEERFIELD SPECIAL SITUATIONS FUND, L.P. (“DFSS”) and DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P. (together with DPDF, DFPDI and DFSS, collectively referred to as the “Lenders” and together with the Borrower, the “Parties”).

RECITALS:

1. Borrower and the Lenders have entered into that certain Facility Agreement and Registration Rights Agreement, each dated as of March 31, 2014 (as the same may be amended, modified, restated or otherwise supplemented from time to time, the “Facility Agreement” and “Registration Rights Agreement”).

2. The Parties desire to amend the Facility Agreement to extend the time for the payment of and to provide that the Yield Enhancement Payment may be payable in shares of Common Stock of the Borrower, subject to the conditions and provisions set forth herein.

NOW, THEREFORE, in consideration of the mutual agreements contained herein, the Parties agree as follows:

1. Defined Terms. Capitalized terms used herein which are defined in the Facility Agreement, unless otherwise defined herein, shall have the meanings ascribed to them in the Facility Agreement and the Registration Rights Agreement. The Recitals to this Amendment are incorporated herein in their entirety by this reference thereto.

2. Amendments to Facility Agreement.

a. The definition of “Yield Enhancement Payment” in Section 1.1 of the Facility Agreement is amended in its entirety to read as follows:

“Yield Enhancement Payment” means an amount equal to three percent (3%) of the outstanding principal amount of the Notes payable by the issuance to the Lenders of duly authorized shares of Common Stock of the Borrower valued at the Yield Enhancement Price.

b. Section 1.1 of the Facility Agreement is amended to add thereto the following additional defined terms:

“Freely Tradable Date” means the earlier of (i) the date on which the Registration Statement (as defined in the Registration Rights Agreement) covering all of the Yield Enhancement Shares is declared effective or (ii) the first date that all of the Yield Enhancement Shares are eligible for resale by the Lenders that are not affiliates (as defined in Rule 144(a)(1) under the Securities Act) of the Borrower without restriction and without the need for registration under any applicable federal or state securities laws.

“Freely Tradable Price” means the Volume Weighted Average Price (as defined in Section 2.9(e)) for the Borrower’s Common Stock for the five (5) consecutive Trading Day period beginning on the Trading Day immediately following the Freely Tradable Date.

“First Amendment to Facility Agreement” means the First Amendment to Facility Agreement and Registration Rights Agreement dated as of June 25, 2014 between Borrower and Lenders.

“Yield Enhancement Filing Date” means the date on which the Yield Enhancement Registration Statement is filed with the Securities and Exchange Commission.

“Yield Enhancement Payment Date” shall have the meaning provided in Section 2.3(e).

“Yield Enhancement Price” means the lesser of (i) the Volume Weighted Average Price (as defined in Section 2.9(e)) for the Borrower’s Common Stock for the five (5) consecutive Trading Day period prior to the Yield Enhancement Payment Date (as defined in Section 2.3(e) below) or (ii) the closing bid price for the Borrower’s Common Stock as of the last Trading Day prior to the Yield Enhancement Payment Date on the principal securities exchange, trading market or quotation system (including the OTC Markets) on which the Borrower’s Common Stock is listed, traded or quoted, provided, however, that, in the case of clause (ii), such price shall be no less than 93% of the last closing price for the Company’s Common Stock during regular trading hours on such date.

“Yield Enhancement Registration Statement” means a Registration Statement (as defined in the Registration Rights Agreement)covering the resale of the Yield Enhancement Shares.

“Yield Enhancement Shares” means the shares of the Borrower’s Common Stock issuable to the Lenders pursuant to Section 2.3(e).

c. Section 2.3(e) of the Facility Agreement is hereby amended in its entirety to read as follows:

“ On July 9, 2014 (the “Yield Enhancement Payment Date”), the Borrower shall make a Yield Enhancement Payment to the Lenders in accordance with the respective allocations set forth on Schedule 1 hereto. In the event that (i) the Freely Tradable Date does not occur within twenty (20) Trading Days following the Yield Enhancement Filing Date and (ii) the Freely Tradable Price is less than the Yield Enhancement Price (appropriately reflecting any stock splits, stock combinations, recapitalizations or other similar events), then the Borrower shall make a cash payment to the Lenders (in accordance with the respective allocations set forth on Schedule 1 hereto) within seven (7) Business Dates following the Freely Tradable date in an amount equal to product of the number of Yield Enhancement Shares multiplied by the difference between (x) the Yield Enhancement Price and (y) the Freely Tradable Price. The Borrower agrees that no later than two (2) Trading Days following the Freely Tradable Date (subject to prior delivery by the Lenders to the Borrower or its transfer agent of the certificates representing the Yield Enhancement Shares) it shall deliver or cause to be delivered to the Lenders certificates representing such shares that are free from all restrictive or other legends, or, at the option of the Lenders, provided the Borrower’s transfer agent is participating in the DTC Fast Automated Securities Transfer (“FAST”) program, the Borrower shall cause its transfer agent to electronically transmit such shares by crediting the account of the Lenders’ prime broker with DTC through its Deposit Withdrawal Agent Commission (DWAC) system during such two (2) Trading Day period.

d. Schedule 1 to the Facility Agreement is hereby deleted in its entirety and schedule 1 attached hereto is inserted in substitution therefor.

3. Amendments to the Registration Rights Agreement.

a. The definition of “Facility Agreement” in the Registration Rights Agreement is hereby deleted in its entirety and the following is inserted in substitution thereof:

“Facility Agreement” means the Facility Agreement between the parties hereto, dated as of March 31, 2014, as amended by the First Amendment to Facility Agreement and Registration Rights Agreement, dated as of June 25, 2014, as amended, modified, restated or supplemented from time to time.

b. The date of delivery of the Yield Enhancement Shares shall be deemed an “Issuance Date” under the Registration Rights Agreement.

c. The definition of “Filing Deadline” in the Registration Rights Agreement is hereby deleted in its entirety and the following is inserted in substitution thereof:

“Filing Deadline” for each Registration Statement required to be filed hereunder other than Section 2(a)(ii), shall mean a date that is fifteen (15) calendar days following the applicable Issuance Date, and, in the case of Section 2(a)(ii), shall mean the Additional Filing Deadline, provided, however, that the first Filing Date shall be not be required to be prior to July 10, 2014, provided that the Registration Statement required to be filed on or prior to such date include all Registrable Securities issued prior to such date and that the failure to file such Registration Statement by such date shall constitute and Event of Default under the Facility Agreement regardless of any cure period set forth therein.

4. Representations and Warranties. Borrower hereby represents and warrants to Lenders as follows:

a. As of the date hereof, the representations and warranties of Borrower contained in the Loan Documents are (i) in the case of representations and warranties qualified by “materiality,” “Material Adverse Effect” or similar language, true and correct in all respects and (ii) in the case of all other representations and warranties, true and correct in all material respects, in each case on and as of the date hereof, except to the extent that any such representation or warranty relates to a specific date, in which case such representation and warranty shall be true and correct in all respects or all material respects, as applicable, as of such earlier date;

b. The execution, delivery and performance by Borrower of this Amendment (i) are within Borrower’s corporate powers, (ii) have been duly authorized by all necessary action pursuant to its Organizational Documents, (iii) require no further action by or in respect of, or filing with, any Government Authority, and (iv) do not violate, conflict with or cause a breach or a default under any provision of applicable law or regulation or of Borrower’s Organizational Documents or of any agreement, judgment, injunction, order, decree or other instrument binding upon Borrower, except to the extent such violation, conflict, breach or default would not individually or in the aggregate reasonably be expected to have a Material Adverse Effect;

c. This Amendment constitutes the valid and binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws relating to the enforcement of creditor’s rights generally and by general equitable principles;

d. No Event of Default exists; and

e. The Yield Enhancement Shares have been duly authorized and when issued and delivered in accordance with the terms of the Facility Agreement, will have been validly issued and will be fully paid and nonassessable. There are no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon the voting or transfer of any shares of Common Stock pursuant to the Borrower’s Organizational Documents or any agreements to which the Borrower or any of its Subsidiaries is a party or by which the Borrower or any of its Subsidiaries is bound.

5. No Further Amendments; Ratification of Liability. Except as amended hereby, the Facility Agreement and each of the other Loan Documents shall remain in full force and effect in accordance with their respective terms. Borrower as debtor, grantor, pledgor, guarantor or assignor, or in any similar capacity in which it has granted Liens or acted as an accommodation party or guarantor, as the case may be, hereby ratifies, confirms and reaffirms its liabilities, its payment and performance obligations (contingent or otherwise) and its agreements under the Facility Agreement and the other Loan Documents, all as amended by this Amendment, and the liens and security interests granted, created and perfected thereby. The Lenders’ agreement to the terms of this Amendment or any other amendment of the Facility Agreement or any other Loan Document shall not be deemed to establish or create a custom or course of dealing among Borrower, Lenders, assignees, or any of them. This Amendment, together with the other Loan Documents, contains the entire agreement among Borrower and Lenders contemplated by this Amendment.

6. Incorporation by Reference. The provisions of Article 5 of the Facility Agreement are incorporated herein by reference mutatis mutandis.

7. Expenses. .. The Borrower shall reimburse the Lenders for their reasonable and documented out-of-pocket expenses, including the reasonable and documented out-of-pocket legal fees and costs, incurred in connection with the documentation of, and the consummation of the transactions contemplated by, this Amendment.

[Remainder of Page Intentionally Left Blank, signature page follows]

IN WITNESS WHEREOF, the parties have executed this Amendment as of the date set forth above.

BORROWER:
CYTOMEDIX, INC.
By:	/s/ Martin P. Rosendale
Name:	Martin P. Rosendale
Title:	Chief Executive Officer
LENDERS:
DEERFIELD PRIVATE DESIGN FUND II, L.P.
By:	Deerfield Mgmt., L.P., its General Partner
By:	J.E. Flynn Capital, LLC, its General Partner
By:	/s/ James E. Flynn
Name:	James E. Flynn
Title:	General Partner
DEERFIELD PRIVATE DESIGN INTERNATIONAL II, L.P.
By:	Deerfield Mgmt., L.P., its General Partner
By:	J.E. Flynn Capital, LLC, its General Partner
By:	/s/ James E. Flynn
Name:	James E. Flynn
Title:	General Partner
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By:	Deerfield Mgmt., L.P., General Partner
By:	J.E. Flynn Capital, LLC, General Partner
By:	/s/James E. Flynn
	James E. Flynn, President
DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P..
By:	Deerfield Mgmt, L.P., General Partner
By:	J.E. Flynn Capital, LLC, General Partner
By:	/s/James E. Flynn
	James E. Flynn, President

EX-99.1

FOR IMMEDIATE RELEASE

CYTOMEDIX COMPLETES THE SECOND TRANCHE OF THE $35 MILLION CONVERTIBLE DEBT FINANCING WITH DEERFIELD MANAGEMENT COMPANY

GAITHERSBURG, Maryland – June 26, 2014 – Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, today announced receipt, following satisfaction of closing conditions, of the second tranche of the gross proceeds in the amount of $26 million (for a total $35 million) in convertible debt financing from certain investment funds managed by Deerfield Management Company, L.P. Under the terms of the Facility Agreement dated as of March 31, 2014, Deerfield agreed to provide to the Company up to $35 million in financing through a senior secured convertible debt facility. The commitment consisted of two separate tranches, of which the first $9 million was received upon initial closing of the transaction on March 31, 2014. The second tranche in the gross amount of $26 million was completed as anticipated. As previously disclosed, the notes have a fixed conversion price of $0.52 per share. Following the retirement of debt and payment of certain expenses associated with the closing of the second tranche, the net proceeds to the Company were approximately $22.1 million.

“The successful completion of this financing with Deerfield will allow us to proceed with the implementation of our commercial strategy to provide a therapeutic and cost effective alternative for patients suffering with chronic wounds,” said Martin Rosendale, Cytomedix Chief Executive Officer. “We continue to believe that AutoloGel’s efficacy across a wide range of wound types combined with our recently granted Medicare coverage, provides a tremendous opportunity for patients, caregivers and the Company. We are appreciative of Deerfield’s commitment to Cytomedix and highly value their now increased and significant financial partnership with us.”

About AutoloGel

The AutoloGel System utilizes a proprietary unique technology that enables the rapid isolation and activation of PRP from a patient's own blood. The PRP is subsequently processed to produce a bioactive gel for application to the wound bed, re-establishing a balance needed for natural healing to occur. In normal healing, platelets migrate from the blood into the wound site where they serve as the primary source of growth factors for effective wound healing. In chronic wounds, blood supply may be impaired and the delivery of platelets is impeded, disallowing adequate concentrations of growth factors. The AutoloGel System is used at the point-of-care and is the only PRP system cleared by the U.S. Food and Drug Administration for use on exuding wounds, such as leg ulcers, pressure ulcers and diabetic ulcers, and for the management of mechanically or surgically-debrided wounds. Cytomedix's clinical studies have shown that AutoloGel rapidly and more effectively improved healing compared with control-treated wounds. This has been demonstrated in a variety of clinical studies including a systematic review of 21 comparison studies and a number of other observational and case series publications as well.

About Cytomedix

Cytomedix, Inc. is an autologous regenerative therapies company commercializing innovative platelet technologies for wound care. The Company markets the AutoloGel(TM) System, a device for the production of autologous platelet rich plasma ("PRP") gel for use on a variety of exuding wounds. For additional information please visit cytomedix.com.

Safe Harbor Statement

Statements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, the Company's ability to successfully undertake the commercial launch of AutoloGel™ system, and to execute on its strategy to market this system as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect future operating results are more fully described in Company U.S. Securities and Exchange Commission filings, including the Annual Report for the year ended December 31, 2013, and other subsequent filings. These filings are available at www.sec.gov.

Contacts:
Cytomedix, Inc.	Investors
Martin Rosendale, Chief Executive Officer	Andrew McDonald Ph.D.
Steven A. Shallcross, EVP/Chief Financial Officer	LifeSci Advisors, LLC
(240) 499-2680	andrew@lifesciadvisors.com
(646) 597-6987

# # #